Johnson & Johnson (JNJ) has seen its stock surge over 52% in the past year, but the company’s recent Q1 2026 earnings report led to a slight dip in share price despite beating estimates and raising guidance. Key revenue drivers included Darzalex, generating $4 billion, and Tremfya, which brought in $1.6 billion. However, concerns linger over the significant drop in sales of Stelara, which fell from $1.6 billion to $656 million following its patent expiration and the rise of generics.

This muted market reaction highlights the challenges J&J faces, particularly in managing the impact of patent expirations on revenue streams. While the company maintains a robust drug pipeline and a strong history of dividend growth, the elevated forward price-to-earnings ratio suggests that investors may need to exercise caution in the short term.

For market professionals, the key takeaway is that while J&J presents a blend of stability and growth potential, the recent earnings report underscores the importance of closely monitoring patent-related risks and competitive pressures in the pharmaceutical sector.

Source: fool.com